Executive Chairman at A BetterLife Pharma
I'm Executive Chairman of A BetterLife Pharma, and I was Founding CEO of Alvogen.
After nine months advising, I became chair. We closed a US$100M round, unusual for a preclinical company.
I write Katogen Insights, and I own my misses: my semaglutide model had one dial, the business had two.
CYB003 earned FDA Breakthrough Therapy status, with about 75% of patients in remission after two doses.
I led the recapitalization of a contract maker of DEA-scheduled pills, and we made the Inc. 5000 list.
We hit positive EBITDA in two quarters and launched a direct-to-patient pharmacy. Value rose from $80M to $800M.
My first CEO job. Impatient investors and my mentor Róbert Wessman pushed us hard, and it later sold for about $2B.
As head of M&A I also sat on the executive board, and we raised $3 billion.
I did a lab sciences course at Anglia Ruskin, then a BSc in microbial and molecular biology at East Anglia.
Executive Chairman at A BetterLife Pharma
I'm Executive Chairman of A BetterLife Pharma, and I was Founding CEO of Alvogen.
After nine months advising, I became chair. We closed a US$100M round, unusual for a preclinical company.
I write Katogen Insights, and I own my misses: my semaglutide model had one dial, the business had two.
CYB003 earned FDA Breakthrough Therapy status, with about 75% of patients in remission after two doses.
I led the recapitalization of a contract maker of DEA-scheduled pills, and we made the Inc. 5000 list.
We hit positive EBITDA in two quarters and launched a direct-to-patient pharmacy. Value rose from $80M to $800M.
My first CEO job. Impatient investors and my mentor Róbert Wessman pushed us hard, and it later sold for about $2B.
As head of M&A I also sat on the executive board, and we raised $3 billion.
I did a lab sciences course at Anglia Ruskin, then a BSc in microbial and molecular biology at East Anglia.
By using this service, you agree to the Terms of Service and Privacy Policy.